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Abstract: Metabolic system modeling for model-based glycaemic control is becoming 
increasingly important. Few metabolic system models are clinically validated for both fit to the 
data and prediction ability. This research introduces a new additional form of pharmaco-dynamic 
(PD) surface comparison for model analysis and validation. These 3D surfaces are developed for 
3 clinically validated models and 1 model with an added saturation dynamic. The models include
the well-known Minimal Model. They are fit to two different data sets of clinical PD data from 
hyperinsulinaemic clamp studies at euglycaemia and/or hyperglycaemia. The models are fit to 
the first data set to determine an optimal set of population parameters. The second data set is 
used to test trend prediction of the surface modeling as it represents a lower insulin sensitivity 
cohort and should thus require only scaling in these (or related) parameters to match this data set. 
This particular approach clearly highlights differences in modeling methods, and the model 
dynamics utilized that may not appear as clearly in other fitting or prediction validation methods. 
Across all models saturation of insulin action is seen to be an important determinant of 
prediction and fit quality. In particular, the well reported under-modeling of insulin sensitivity in 
the Minimal Model can be seen in this context to be a result of a lack of saturation dynamics, 
which in turn affects its ability to detect differences between cohorts. The overall approach of 
examining PD surfaces is seen to be an effective means of analyzing and thus validating a 
metabolic model’s inherent dynamics and basic trend prediction on a population level, but is not 
a replacement for data driven, patient-specific fit and prediction validation for clinical use. The
overall method presented could be readily generalized to similar PD systems and therapeutics.
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1.0 INTRODUCTION
Type 1 and Type 2 diabetes are epidemic [1-3] with significant economic cost [4-7], driven by 
the inability of individuals and their clinicians to achieve consistent adequate control of blood 
glucose levels [8-10]. Hence, the rate of costly chronic complications is rising. In addition, 
critical care and surgical studies have shown that successfully providing tight glycaemic control 
can significantly reduce mortality [11-14] and cost [15, 16]. However, achieving it has proven 
difficult, even though initial results show tighter control may be better [17, 18]. 
The potential of models for managing glycaemic levels in any insulin resistant cohort is thus of 
growing import. However, relatively few models have been clinically validated. For most
models, the primary form of validation has been simple fitting of the model to match clinical 
data [19]. Occasionally, more rigorous prediction validation, which tests the models ability to 
predict the outcome of a known intervention on retrospective clinical data (or in a clinical trial)
is used. However, only a few clinically validated models can predict within clinically acceptable 
ranges [20-26]. 
This paper presents a new form of model validation that examines the steady state pharmaco-
dynamic (PD) surfaces, including underlying pharmaco-kinetics (PK). It is thus a means of 
analysing the fundamental model dynamics used over a range of input and response variables. 
Comparison to clinical data points on this surface can provide a means of validating the model’s 
underlying dynamics.
In this research, a 3D surface of plasma insulin (x), plasma glucose (y) and resulting rate of 
change in endogenous glucose balance (z) is compared to 77 sets of glycaemic clamp data from 
individuals with relatively high insulin sensitivity [20]. The resulting models are then assessed 
   
on a further 146 glycaemic clamps from a before-after intervention study of 73 normo-
glycaemic, high BMI (BMI > 30) individuals [27] with relatively lower insulin sensitivity to 
determine whether the identified models and resulting PD surfaces can predict the new values by 
changes in insulin sensitivity. The overall approach is thus used to present and initially validate 
this new approach to metabolic system model validation in this comparison. 
2.0 METHODS
2.1  Models:
Three clinically validated models are used in this analysis:
1. Non-linear PK/PD Model (ND)
2. Minimal Model (MM)
3. Receptor Model (RM)
The ND model has been used in several critical care studies [23, 28, 29], for insulin sensitivity 
testing and analysis [25, 30], and in prediction validation of a model for controlling type 1 
diabetes [24]. The MM is well documented and used [31-37]. The RM model was developed for 
a Type 1 diabetes decision support system [20] and recently extended for critical care control 
[26]. 
The dynamic system models (MM, ND) share the same basic PD formulation and can be jointly 
defined [25]. However, for clarity, the ND models are defined:
   
where G(t) [mmol/L] is the total plasma glucose, Q(t) [mU/L] is the interstitial insulin 
concentration, which is assumed equal to plasma insulin concentration in this steady state 
analysis although other reasonable steady state ratios could be used equally well. Finally, P(t)
[mmol/min] is exogenous carbohydrate appearance, Pend [mmol/min] represents endogenous 
glucose appearance in a glucose distribution volume VG. Patient endogenous glucose clearance 
and insulin sensitivity are pG [1/min] and SI [L/(mU.min)]. Michaelis-Menten function αG
[L/mU] captures saturation of plasma insulin disappearance and glucose uptake by insulin, and 
αG2 [L/mmol] allows for the saturation of glucose-dependent glucose clearance. 
The ND model thus has two forms. The first and extensively used form sets αG2 = 0, saturating 
only the available insulin for action to remove glucose. The second, has non-zero values for both 
saturation terms αG2 and αG. Thus, these variants (ND1 a sub-case of ND2) can be used to
examine the need for saturating both the available insulin and the available glucose, in 
comparison to clinical clamp data over the PD surface. Thus, it can be determined if both 
saturation dynamics are required, or if saturating just available insulin sufficient.  
The Minimal Model (MM) is thus effectively the case where: Pend = αG2 = αG = 0. In addition, 
the term -pG*G is redefined as -pG*(G-GE), where GE is a basal glucose value not used in the ND 
model of Equation (1), but defined in the MM [33], and SI is the ratio of p2 and p3 that is used in 
the original and common MM formulations [32, 33]. The MM model is thus defined here as:
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where G(t) [mmol/L] is the plasma glucose level above an equilibrium or basal level GE
[mmol/L], and all other terms are as defined in Equation (1a). Equations (1a) and (1b) are 
numbered this way to highlight their similarity. In particular, as noted, there are several 
similarities between the ND1,2 and MM models. However, the PD surfaces are very different 
due to the differences in specific dynamics included, which this analysis and validation approach 
can highlight.
In this steady state PD surface analysis, Q(t)  Qss and G(t)  Gss thus indicating steady state 
values, as found in glycaemic clamp testing to assess insulin sensitivity in vivo. Hence, the rate 
of change of glucose is (negatively equivalent) in Equations (1a,b) to the endogenous balance 
change for that input in the steady state (Ġ  Pss). Therefore, the glucose infusion required to 
maintain a glycaemic level in a glycaemic clamp test, at steady state, is assumed equivalent to 
the drop or change in glucose (Ġ), referred to here as change in the endogenous balance, that 
would result from the same steady state plasma and interstitial insulin (Qss), and plasma glucose 
(Gss) values. Thus, the steady state ND and MM model pharmaco-dynamics based on glycaemic 
clamp test results can be ascertained using versions of Equations (1).
More specifically, the glucose infusion Pss in the clamp required to hold steady state glucose Gss, 
at infusion resulting in steady state plasma insulin Iss  Qss, is equated to the potential rate of 
change (drop) in blood glucose if that infusion had not been given. Thus, it is a steady state 
approximation of the change in glucose at a given level of insulin and blood glucose (in steady 
state). The steady state assumption provides a unique surface for these dynamic models (ND, 
MM) and relates this surface to readily available euglycaemic clamp data.
   
The receptor model (RM) takes a different approach to modeling this system and is defined from 
a series of prior works as [20, 26]: 
where G is the plasma glucose concentration, Is is the saturated or available plasma insulin, I.
and all terms and values are as defined in [20, 26]. 
The RM is defined based on clinically observed gains/losses from the liver (Hepatic), and losses 
to the kidneys (Renal), insulin-dependent periphery (P14) and insulin-independent periphery 
(P13). Hence, this receptor based model is physiologically defined. Finally, Is is a saturated 
insulin effect for insulin-dependent uptake, and it should be noted that P13 is a saturable insulin 
independent uptake of glucose and P14 a saturable insulin dependent uptake. The other specific 
values were obtained by fitting to 77 clinical glycaemic clamp studies, so that this model is 
already identified for that original data set. 
The net results of this model (EndoBal) creates the 3D PD surface used for this comparison. This 
term is equivalent to the change in endogenous balance as obtained from glycaemic clamp data
(Ġ) defined previously for the dynamic models of Equations (1). The PD surface is thus
mathematically defined for the MM and ND models, and a direct output of the RM model. 
Again, note that the RM model was created by directly fitting to clinical data, and thus needs no 
further alteration or analysis.
EndoBal = Hepatic – Renal – P13 – P14 (2)
Hepatic = -0.46min-1 G – 1.475mmol/min/mU Is + 1.259mmol/L/min;    Gmax=12.0 mmol/L (3)
Renal = 0.004L/mmol/min G2 – 0.064min-1 G + 0.278mmol/L/min (4)
P13 = 0.56min-1 *G/(G + 1.5mmol/L) (5)
P14 = 5.09mmol/L/min/mU G*Is /(G+5.0 mmol/L) (6)
Is = I * 1/((I-0.083mU/L)
1.77+ (0.539mU/L)1.77)(1/1.77) (7)
   
2.2 Clinical Data Sets:
There are two sets of clinical data from glycaemic clamp studies. The first set covers 77 
glycaemic clamp tests over 15 reported studies, as used and reported in [20]. These tests were 
primarily on subjects with relatively normal or elevated insulin sensitivity, as found in exercise 
based studies. They cover a range hyperinsulinaemic glycaemic clamp tests at both euglycaemia 
(n = 72) and hyperglycaemia (n = 5), for an insulin sensitive cohort.
The second data set consists of 146 hyperinsulinaemic euglycaemic clamps done on 73 subjects 
around a 3-month lifestyle intervention of varying intensity [27]. The subjects were normo-
glycaemic with elevated body mass index (BMI) levels of BMI > 30. One test was done before 
the intervention and a second after to also assess the impact on insulin sensitivity. This is a 
normal to reduced insulin sensitivity cohort with modest increases in this metric after the 
intervention.
2.3 PD Surface Fitting Method:
To fit the PD surface for the ND and MM cases, a grid search was used over physiological 
ranges of important variables. In this case, the values or equations for Pend and VG are well 
reported and thus set to constants, as shown in the top portion of Table 1 and discussed or 
reviewed in [20, 30, 38-40]. Hence, the values of PG, αG2, αG, SI were allowed to vary. The 
physiological ranges for αG2, αG, SI are based on an extensive literature search [41], model 
validation and sensitivity study [42], and are shown in the lower portion of Table 1.
Note that the variables αG2, αG can be set to zero in the ND model as well. Hence, there are two 
models that arise in this regard. The ND1 model sets αG2 = 0 for all cases, considering only 
saturation on the insulin available for action at the receptor. In contrast, the ND2 model has non-
   
zero values for both αG2 and αG, considering saturation at both the insulin receptor and of the 
glucose available for uptake. The latter case matches the saturation dynamics used in the RM 
model. The MM case sets both to zero, as noted.
Table 1: Variable values used in ND and MM analyses
Variable Value  increment
Pend 1.2 mmol/L/min     (= 0 for MM) -
VG
VG = 0.19*Mass (kg)13.3 L (for 70kg 
indiv)
-
PG 1.0e-3 – 1.0e-1  = 1.0e-3
SI 1.0e-4 – 1.0e-2 L/mU/min   = 1.0e-4
αG 0 and 1/20 – 1/80 L/mU    (= 0 for MM)  = +1.0 in denominator [1/20, 1/21, …, 1/80]     
αG2 0 and 1/5 – 1/20 L/mmol   (= 0 for MM)  = +1.0 in denominator [1/5, 1/6, 1/7, …, 1/20]
The overall approach is to first find values for the variables in the lower half of Table 1 for each 
model (ND1, ND2 and MM) that best fit the data from the 77 clamp studies. The second 146 
clamp data set is used to evaluate these identified PD surfaces and models. Given that the main 
difference between these data sets is a general reduction in insulin sensitivity, the second set of 
data should be reasonably, although not optimally, fit by reducing insulin sensitivity alone. This 
hypothesis will be tested by re-fitting the data to these clamps by grid search over all variables, 
as well as only over the insulin sensitivity variable.
Thus, for each set of variables in the lower part of Table 1, Ġ = -Pss is calculated from the model 
at the (Qss, Gss) from each clamp result. For example, the first data set thus creates 77 sets of 
(Qss, Gss)Ġ = -Pss points for each combination of (αG2, αG, SI). Importantly, this approach 
assumes that the steady state glucose infusion in the clamp (Pss) is the negative of the glucose 
rate of change (Ġ) that would occur without it. Hence, these terms represent the same value, with 
Pss for the clamp infusion to maintain euglycaemia and Ġ for the equivalent endogenous balance 
   
change that would occur for the given glucose and insulin levels without it. The difference is in 
the sign with Pss positive and Ġ negative in this usage. 
This approach takes the several possible z = -Pss values for a given (x,y) = (Qss, Gss) pair and 
finds a single best value over the parameters in Table 1. It does so via fitting the data to 
minimum error metrics over these variables in a grid search looking for a best error fit. The 
result is that the identified surface thus has one z value for a given (x,y) pair with the identified 
parameters, found via the use of clinical euglycaemic clamp data. From fitting each model 
comparisons can be drawn to evaluate each models dynamics.
2.4 Error Metrics:
Overall, the ND2 model examines 9.76e+6 combinations, the ND1 model 0.61M, and the MM 
model 10,000. The values decrease due to the reduction in non-zero variables in each case. Each 
combination results in an error for each clamp study examined (77 or 146 respectively), which 
are summarised in two forms:
1. RMS Error (RMS) – an average error metric, it rewards solutions that minimise error 
over all studies consistently without regard to distribution or the mode of the error 
distribution, which should ideally approach zero.
2. Frequency of Error Near Zero (FNZ) – number of errors within +/-0.025 of 0.000 error 
value or ~5% of mean Ġ observed in the clinical studies. This metric rewards solutions 
that have greater concentrations within the reported glycaemic clamp variability of ~5%
[30] around zero (0.0), regardless of the exact mode of the error or outliers due to 
variations in testing conditions or method across studies.
   
Each error metric rewards a different quality of fit. RMS minimises outliers, without accounting 
for outlying clinical results or variation. AME rewards solutions that maximise “inliers” but not 
to a specific value. FNZ rewards “inlier” solutions within clinically observed variability for 
glycaemic clamps, allowing outliers for study variability and error. Ideally, each error metric 
would be minimised for the same variable set, or a very nearly identical set with similar 
minimum error values. 
3.0 RESULTS & DISCUSSION
3.1 Model Identification and Analysis on First Clinical Data Set:
Table 2 shows the results for identification over the 77 clamp studies from Arleth et al [20]. The 
minimum error set of model variables was the same over both error metrics in each case. Figures 
1-4 show waterfall plots of the 3D PD surfaces around the glucose levels in the 77 clamp data for 
the MM, ND1, ND2 and RM models, respectively. Ideally, the waterfall lines of constant 
glucose level in these plots should pass through the clinical data at that same glucose level. The 
specific waterfall lines are plotted at (highest or top to lowest or bottom): [4.0, 4.5, 5.0, 5.5, 6.0] 
mmol/L for the euglycaemic clamp data (left plot in Figure 1); and [7.0, 9.5, 10.5, 11.5] mmol/L 
for the hyperglycaemic clamp data (right plot in Figure 1).
   
Table 2: Results (parameter values and errors for all models, where the best error values 
occur, in all cases, for the same parameter value sets.
Model Values and Error Performance
MM
αG = αG2 = 0 L/mU & L/mmol  (as assumed)
SI = 0.0001 L/mU/min;     
PG = 0.024
RMS = 0.29
FNZ = 24 (of 77)
ND1
αG = 1/47 L/mU;              αG2 = 0 L/mmol, 
SI = 0.0016 L/mU/min;     
PG = 0.006
RMS = 0.07
FNZ = 37 (of 77)
ND2
αG = 1/47 L/mU;               αG2 =1/6 L/mmol, 
SI = 0.0031 L/mU/min;      
PG = 0.006
RMS = 0.05
FNZ = 39 (of 77)
RM
Parameters as in Equations (1)-(7) – model fitted to this data set
RMS = 0.04
FNZ = 32 (of 77)
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Figure 1: Left: MM waterfall with lines showing constant glucose at Gss = 4.0, 4.5, 5.0, 5.5 and 
6.0 mmol/L.  Clinical Studies: Squares: Gss = 4-4.75 mmol/L, Circles: Gss = 4.75-5.25 mmol/L 
and Triangles: Gss = 5.25-6.0 mmol/L; Right: MM waterfall with lines showing constant glucose 
at Gss = 7.5, 9.5, 11.5, 12.5 mmol/L.  Clinical Studies: Circles: Gss = 7-8 mmol/L studies, 
Triangles: Gss = 9-10 mmol/L, Squares: Gss = 10-11 mmol/L, and the X is 12-13 mmol/L. The 
lowest and highest valued (top and bottom in plot) waterfall lines of constant glucose are labelled 
for clarity.
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Figure 2: ND1 waterfall plots with data as defined in Figure 1 and on the same axes.
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Figure 3: ND2 waterfall plots with data as defined in Figure 1 and on the same axes.
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Figure 4: RM waterfall plots with data as defined in Figure 1 and on the same axes. The fit is 
essentially ideal as the saturation term of Equation (7) was defined to match this first set of 77 
glycaemic clamp data.
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Five results can be obtained directly from Figures 1-4 and Table 2:
1. The MM identification can fit only one regime (euglycaemia or hyperglycaemia) well, 
while the same constants do not capture data from the other regime. As a result, errors are 
relatively much larger despite abnormally low insulin sensitivity values, where the value 
SI = 1.0e-4 in Table 2 is at the same level as a highly insulin resistant critical care patient 
[42-44]. Hence, the MM model is distinctly different, trying to adapt to its lack of 
dynamics by a lower SI value, matching reported under prediction when used in clamp 
studies [45, 46].
2. The ND1 and ND2 models provide qualitatively good fits with little difference between 
them and exactly the same parameters for αG and PG. The added saturation dynamics in 
both models enable the waterfall lines of constant glucose to capture the data in each 
regime well, as these lines also reflect the clinically observed saturation dynamics as 
steady state insulin levels increase [47, 48].
3. The RM model provides the best fit to the clinical data due primarily to the very sharp 
insulin saturation curve provided by Equation (7), which was defined to match this data. 
4. The ND1 and ND2 models have higher FNZ than the RM model, but also slightly greater 
RMS error, indicating that the ND1 and ND2 models capture the central data slightly 
better, but with greater outliers than the RM model.
5. The Michaelis-Menten glucose saturation level at 5 mmol/L in Equation (6) is close to 
equivalent to the G2 = 1/6 value in the ND2 model. Hence, given the small differences in 
error between the ND1 (G2 = 0), ND2 and RM models for this data, it might be 
concluded that this second saturation of available glucose plays only a very minor role in 
this surface with respect to this data and might therefore be eliminated.
   
These results are relatively novel in the field, which tends to examine models with respect to 
individual tests or outcomes, creating patient specific models and predictions. Hence, over a 
cohort of data, these results indicate that the ND1, ND2 and RM models perform similarly, while 
the MM model may not match more than a given (and thus patient specific) regime at a given set 
of model variables. Finally, there is some evidence that the saturation dynamics of insulin, at the 
receptor, may be more sharply non-linear than is best represented by the well-accepted 
Michaelis-Menton saturation model [49], as is illustrated schematically in Figure 5.
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Figure 5: Comparison of insulin saturation curves, where the no saturation curve is the linear 
line seen in the MM case.
The sharper, highly non-linear saturation curve seen in Figure 5 also results in the closer lines of 
constant glucose in Figures 4. The softer Michaelis-Menten term only offers the wider glucose 
curves in Figures 2-3. Thus, the ND models provide a lesser fit to this clinical data, which is 
more sharply saturated, as seen at the euglycaemic glucose values in Figures 2-3. Note that while 
the ND2 model of Figure 3 is tighter with its second saturation, it is still not sharp enough to 
capture all the clinical data shown. This result thus suggests that there is a different saturation 
dynamic physiologically than is captured (fully) by Michaelis-Menten terms, at least over this 
range of clinical studies.
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3.2 Model Prediction Based on Identification of the Second Clinical Data Set:
Table 3 shows the results of identifying the MM, ND1 and ND2 models for the second data set. 
The RM model insulin sensitivity value of 1.0 for the first data set in Equation (7) was reduced, 
lowering the effect of insulin in Equation (6), to obtain a best match in this case, with all other 
parameters remaining the same. The ideal outcome is to see the best fit models have the same 
variable values (PG, αG2, αG), excepting a lower insulin sensitivity (SI) value to match this less 
insulin sensitive cohort. Thus, a models PD surface might be validated in its ability to capture or 
predict this type of expected change in cohort. Therefore, Table 3 also shows the values from 
Table 2 for comparison to see if this hypothesis holds. If the variable values are the same or very 
similar, this result would validate both a given model’s PD surface and, over all models, the 
general approach presented.
Table 3: Results (parameter values and errors) for 2nd clinical data set of 146 glycaemic 
clamps, with first data set values from Table 2 for comparison. Brackets after SI show 
change in value (in %) from 1st data set for insulin sensitivity.
Model 2nd Data Set Value (146 results) 1st Data Set Values (77 results)
MM
αG = αG2 = 0 L/mU & L/mmol  
SI = 0.0002 L/mU/min (+100%)
PG = 0.024
RMS = 0.06
FNZ = 53 (of 146)
αG = αG2 = 0 L/mU & L/mmol 
SI = 0.0001 L/mU/min;    
PG = 0.024
RMS = 0.29
FNZ = 24 (of 77)
ND1
αG = 1/48 L/mU;  αG2 = 0 L/mmol, 
SI = 0.0013 L/mU/min (-19%)   
PG = 0.006
RMS = 0.05
FNZ = 54 (of 146)
αG = 1/47 L/mU;  αG2 = 0 L/mmol, 
SI = 0.0016 L/mU/min;   
PG = 0.006
RMS = 0.07
FNZ = 37 (of 77)
ND2
αG = 1/47 L/mU; αG2 =1/6 L/mmol, 
SI = 0.0023 L/mU/min  (-26%)      
PG = 0.006
RMS = 0.05
FNZ = 60 (of 146)
αG = 1/47 L/mU;   αG2 =1/6 L/mmol, 
SI = 0.0031 L/mU/min;      
PG = 0.006
RMS = 0.05
FNZ = 39 (of 77)
RM
Insulin Sensitivity = 0.40 (-60%)
RMS = 0.05
FNZ = 61 (of 146)
Insulin Sensitivity = 1.0
RMS = 0.04
FNZ = 32 (of 77)
   
Examining Table 3 two results are readily clear:
1. The MM model does not accurately predict the change in cohort insulin sensitivity, 
despite lower error values and a higher FNZ as a percentage of the total data points 
compared to the first data set. 
2. The ND1, ND2 and RM models all perform as ideally expected and with similar error 
and FNZ values. All three show the expected reduction in insulin sensitivity with 
identical values at the identified best fit for all other parameters.
Overall, the first result is not unexpected in terms of inaccurate prediction and underestimation 
of insulin sensitivity in resistant cohorts [45, 46]. In addition, the MM values found for SI in both 
data sets is relatively very low, comparable to highly resistant critical care patients [42-44], 
which is not representative of the actual status of either clinical data set as neither set had a 
significant T2DM or severely insulin resistant portion [20, 27]. Such underestimation of insulin 
sensitivity is also not unknown with MM analysis [45, 50, 51]. 
Finally, the waterfall curves for this second data set are shown in Figure 6. These figures indicate 
that one reason the MM fits so well is that all the data points are in one euglycaemic range and at 
a relatively constant plasma insulin level. In contrast, the first data set values were spread over a 
wide range of plasma insulin levels and a very wide range of eu- and hyper- glycaemia. As a 
result, the MM fit to the second data set does not have to compromise, as it did for the first data 
set, between this spread of results and can offer, in fact, a better RMS error. More specifically, 
the second set does not as clearly show the saturation dynamics required to fit a range of such 
data that the first data set does. The overall result, is that the insulin sensitivity value for the MM 
case, all else equal, that fits the more insulin resistant second data set is higher than the value 
   
found for the less insulin resistant (more insulin sensitive) first data set – counter to clinical 
expectations and the clinical glycaemic clamp results.
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Figure 6: Waterfall plots with lines and data as defined in Figure 1 for the first data set of 77 
glycaemic clamps, where the diamonds are the data for the second data set of 146 clamp studies 
(empty = pre-intervention, less insulin sensitive and filled = post-intervention). Plots for each 
model case are: (A) MM; (B) ND1; (C) ND2; (D) RM. The original clinical data from the first 
data set, per the Figure 1 definitions, are also shown for comparison. 
Figure 6 also shows the first and second data set clamp results. The difference in insulin 
sensitivity between both groups is evident in that the endogenous balance change is smaller in 
magnitude (less negative) at a given insulin level than the first set. This difference indicates a 
smaller clearance for given steady state insulin levels, and thus lower insulin sensitivity for the 
second data set, in general. Note that this trend also holds for the pre- and post- intervention data 
indicated in these figures, where the post-intervention group is on average at a more negative 
(larger) endogenous balance change value for any given insulin level and thus have a higher 
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insulin sensitivity than before the intervention, matching the results in the original study from 
which this data originated [27].
A final result from Figure 6, in this case, is that the tighter and sharper saturation curves resulting 
from the RM PD surface do not have the same spread over the clinical data that the ND1 and 
ND2 models have. Its spread is also narrower than the linear lines through this data of the MM 
case. Hence, it has a slightly larger RMS error in Table 3.
To further evaluate the issues with the MM surface, the PD surface was re-identified with a 
lower limit of 1.0e-3 for insulin sensitivity (SI) that is tighter than the constraints originally given 
in Table 1. However, the 1.0e-3 value is nearer the values reported in Table 3 for similarly 
derived ND1 and ND2 model structures. This constraint thus forces less underestimation of this 
parameter in favour of other model parameters. The results for are labelled the “Realistic” MM 
case versus the less constrained results labelled the “Best” case originally shown for the MM in 
Table 2. Both are shown in Table 4 for comparison. 
With this constraint the values for SI and SI are both at the lower limits of 1.0e-3. As a result, the 
RMS error increases dramatically, as also evident in the resulting waterfall plots in Figure 7. In 
particular, the Realistic MM case captures a portion of the euglycaemic results for the first data 
set and the less numerous hyper-glycaemic results, where large errors result from those results 
that are missed by large margins in Figure 7. The FNZ also drops significantly, as would be 
expected. Finally, it is thus also evident that good, low error fits of the surface to either data set 
do not exist at variable values above these constraints, and that the trends between data sets will 
also not be matched, as seen previously in Table 3.
   
Table 4: Results for a Realistic and Best case MM identification of PD surface to the first 
clinical data set results (n = 77), with % changes in RMS and FNZ in brackets.
Model Realistic Case 1st Data Set Values Best Case 1st Values from Table 2
MM
αG = αG2 = 0 L/mU & L/mmol  
SI = 0.001 L/mU/min (lower limit)
PG = 0.001
RMS = 3.15                (+1100%)
FNZ = 11 (of 77)        (-45%)
αG = αG2 = 0 L/mU & L/mmol 
SI = 0.0001 L/mU/min;    
PG = 0.001
RMS = 0.29
FNZ = 24 (of 77)
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Figure 7: Waterfall plots for “Realistic” MM case for euglycaemia results (Left) and 
hyperglycaemic results (Right). All lines and clinical data are as defined in Figures 1 and 6 for 
the two clinical data sets.
3.3 Summary and 3D results:
Overall, these results also show how this PD surface analysis can clearly differentiate models
that might not appear so different in other examinations. To further clarify these differences the 
3D PD surfaces are shown in Figures 8 for each model case with the data points from the first 
data set. Note that the figures do not show the detail or level of accuracy of Figures 1-4, 6 and 7. 
However, they clearly show differences due to different saturation dynamics along the glucose 
and insulin axes (x and y), where the vertical (z) axis is the change in endogenous balance.
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Figure 8: 3D PD surface plots optimised for data set 1 with data points shown as filled circles on
the surfaces. (A): RM; (B): MM for realistic case with z-axis 3 times larger than other subplots; 
(C): ND1 and (D): ND2. Note that the MM case with best parameters and very low SI value for 
this data set has the same shape, but lower linear slopes along the glucose and insulin axes. The 
difference in sharpness and number of saturation dynamics is clearer in this view than in the 
waterfall plots of Figures 1-4, 6 and 7.
3.4 Study Limitations:
All models and model-based analyses are estimates of an exact reality and thus have limitations. 
In this study, neither the Michaelis-Menten nor the custom defined RM insulin saturation 
dynamic of Equation (7) appear to be fully generalisable over all the clinical data employed. 
Neither dynamic fully captures the spread or specific sharpness of the saturation over steady 
state insulin values seen in Figures 2-4, 6 and 7. Where the RM case captures the first data set 
well, for which it was defined, it was too narrow or tight for the second set. The opposite appears 
to hold somewhat true for the Michaelis-Menten dynamics used in the ND1 and ND2 models. It 
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is thus likely that some further dynamic model might need to be derived for this particular case 
[49], or a more exact/complex glucose-insulin PD interaction model defined [21, 52, 53] if this 
type of model is to better account for the clinical data shown.
In contrast, there is also significant variability in exactly how a given hyperinsulinaemic clamp is 
delivered, including the insulin dosage and timing in particular. Thus, different groups may 
obtain different results for a given “same” individual, particularly as insulin dosage varies [47]. 
In addition, different methods for adjusting the glucose infusion to maintain glycaemia at a set 
level (eu- or hyper- glycaemic) can also introduce variability beyond the 3-4% C.V. reported for 
the clamp [30]. Hence, it could be argued that some measurable error should be observed 
between the metabolic dynamics of a fixed model and those from a large series of 
hyperglycaemic and/or euglycaemic clamp studies. This last point might be more important if 
these clinical data points are obtained from different clinical groups.
A final limitation in this study is that the second data set contains only euglycaemic clamps 
ranging primarily from 4.0-5.5 mmol/L. They also used the same protocol for each clamp, which 
ensures relatively consistent insulin levels further concentrating the data in one portion of the 
waterfall plots and PD surfaces. Thus, while they are an obviously lower insulin sensitivity 
group cohort than those in the first data set, the model fit to this group may be different due to its 
concentration in one part of the surface. However, it should also be noted that the ND1, ND2 and 
RM models capture this difference directly and with only an appropriate scaling of insulin 
sensitivity. In contrast, the MM is unable to show the same appropriate scaling due to its lack of 
saturation dynamics, and not as a result of where the data are located.
   
It should also be noted that the MM was not designed for this type of supra-physiological testing. 
Its primary use has been in determining insulin sensitivity at lower insulin and glucose doses in 
FSIVGTTs (frequently sampled intravenous glucose tolerance tests) and similar tests [31, 45, 
54]. Hence, at the more supra-physiological levels seen in the clamp this model may be less well 
suited than more non-linear models, although some studies have shown a measure of equivalence 
between the MM enabled FSIVGTT and the clamp [32].
Finally, it is important to note that the PD analysis approach presented should not be seen as a 
replacement for fitting or prediction validations on clinical data using patient-specific models. 
This approach is limited to examining the overall dynamics of a model structure, and the PD 
surface in particular. While this PD surface will define the trend of predictions, as shown here, it 
is not a replacement for patient-specific prediction, particularly if the primary or eventual intent 
is to apply the model in a clinical testing or control scenario. It is thus a tool primarily for 
verifying or validating an overall model structure and the dynamics it includes, rather than a 
validation unto itself.
4.0 CONCLUSIONS
A new PD surface oriented approach to analysing and validating PK and PD system models has 
been presented in the context of metabolic systems models. Two non-linear, physiologically 
representative dynamic models (ND1, ND2), a receptor-based (RM) model, and the well-known 
Minimal Model (MM) were examined. The ND and RM models provide similar dynamics with 
significant differences in the exact modeling method and specific physiological saturation 
dynamics and their definitions that are included. In contrast, the MM is not physiologically 
   
representative enough to provide a 3D surface that captures the clinical data outside specific
insulin and glucose ranges, illustrating the difficulty in using this model for predictive glycaemic 
control. The reported under-prediction of insulin sensitivity by the MM is also clearly evident. 
Comparing ND1 and ND2 shows a potential need to include both saturation terms used in the 
ND2 model due to trade offs between insulin sensitivity and the second saturation term that 
occur in the ND1. The RM model would benefit from validation on additional data in future 
work.
Overall, the method clearly highlights the role and impact of the specific fundamental model 
dynamics. Analysing a model over an entire PD surface, given available clinical experimental 
data, can provide a level of analysis that using one or a few studies will not show. Thus, the MM 
can match limited data points, but not a series of data points over a wide range of the PD surface.
As a result, this approach, particularly used as shown here to capture known trends in data, can 
provide both analytical insight, as well as a validation of the fundamental model dynamics. 
Hence, unnecessary dynamics can be excluded, improving identifiability or computational 
requirements, while missing dynamics may be clearly highlighted. Finally, the overall approach 
is readily generalised to similar system models or physiology.
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